查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1771735

美国原料药CDMO 市场规模、份额和趋势分析报告：按产品、合成、药物、工作流程、应用和细分市场预测，2025 年至 2030 年

U.S. Active Pharmaceutical Ingredients CDMO Market Size, Share & Trends Analysis Report By Product (Traditional API, HP-API, ADC), By Synthesis, By Drug, By Workflow, By Application, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 80 Pages | 商品交期: 2-10个工作天内

价格

市场规模和趋势

2024年，美国原料药 CDMO市值为252.8亿美元，预计2030年将达到338.6亿美元，2025年至2030年期间的复合年增长率为5.1%。这一增长主要源于对先进製药製造服务日益增长的需求，这些服务旨在支持创新药物和治疗方法的开发。此外，对生技药品和高效价API的投资不断增加也推动了市场扩张。慢性病的流行以及对高效、可扩展生产解决方案日益增长的需求也促进了市场的发展。

这一市场成长背后的关键驱动力包括製程化学和製造自动化领域的技术进步，这些进步能够提高产量比率、消除浪费并提升产品品质。鼓励外包给专业CDMO的监管支援至关重要，因为这些组织有助于确保遵守严格的FDA和国际标准。个人化医疗和新型疗法日益受到关注，导致对小规模、复杂原料药製造的需求不断增长，而CDMO凭藉其灵活性和专业知识在这一领域表现出色。製药公司与CDMO之间合作的加强也促进了创新，使公司能够透过缩短上市时间来更好地满足患者不断变化的需求。

这个市场蕴含着巨大的机会，尤其是在生技药品、基因疗法和细胞疗法的开发领域，这些领域需要高度专业的原料药生产。连续生产和流动化学的趋势为CDMO提供了一条途径，使其能够提高效率和可扩展性，同时降低成本和环境影响。

目录

第一章调查方法与范围

第二章执行摘要

第 3 章美国原料药CDMO 市场变数、趋势与范围

  • 市场体系展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
    • 产业挑战
  • 产业分析工具
    • 波特分析
    • PESTEL分析

第四章美国原料药CDMO 市场：依产品估算与趋势分析

  • 美国原料药CDMO 市场（按产品划分）：关键要点
  • 2024 年及 2030 年产品趋势分析及市场占有率
  • 按产品，2018-2030
    • 传统活性药物成分
    • 高效活性药物成分
    • 抗体-药物偶联物（ADC）
    • 其他的

第五章美国原料药CDMO 市场：综合、估算与趋势分析

  • 美国原料药CDMO 市场（按合成）: 关键要点
  • 2024 年及 2030 年综合趋势分析及市场占有率
  • 按成分划分，2018-2030 年
    • 合成
    • 生物技术

第六章美国原料药CDMO 市场：按药物的估计和趋势分析

  • 美国原料药CDMO 市场（按药品类别）：关键要点
  • 2024 年及 2030 年药物趋势分析及市场占有率
  • 依药物分类，2018-2030 年
    • 创新的
    • 非专利的

第七章美国原料药CDMO 市场：依工作流程估算与趋势分析

  • 美国原料药CDMO 市场（按工作流程）：关键要点
  • 2024 年及 2030 年工作流程趋势分析及市场占有率
  • 按工作流程，2018-2030
    • 临床
    • 商业的

第 8 章美国原料药CDMO 市场：按应用估算和趋势分析

  • 美国原料药CDMO 市场（按应用）：关键要点
  • 2024年及2030年应用变化分析及市场占有率
  • 按应用，2018-2030 年
    • 肿瘤学
    • 荷尔蒙
    • 青光眼
    • 心血管疾病
    • 糖尿病
    • 其他的

第九章 竞争态势

  • 公司分类
  • 公司市场定位
  • 公司热图分析
  • 公司简介/上市公司
    • Thermo Fisher Scientific Inc.
    • Novo Group（Catalent, Inc.）
    • Cambrex Corporation
    • Piramal Pharma Limited
    • Corden Pharma
    • Siegfried Holding AG
    • Seqens North America
    • SK pharmteco Inc.
    • Noramco.
    • BSP Pharmaceuticals
Product Code: GVR-4-68040-629-9

Market Size & Trends:

The U.S. active pharmaceutical ingredients CDMO market was valued at USD 25.28 billion in 2024 and is projected to reach USD 33.86 billion by 2030, growing at a CAGR of 5.1% from 2025 to 2030. This growth is driven by rising demand for advanced pharmaceutical manufacturing services to support the development of innovative drugs and therapies. In addition, increasing investments in biologics and high-potency APIs drive market expansion. The growing prevalence of chronic diseases and the need for efficient, scalable production solutions also contribute to the market's momentum.

Key drivers supporting this market growth include technological advancements in process chemistry and manufacturing automation, which improve yield, reduce waste, and enhance product quality. Regulatory support encouraging outsourcing to specialized CDMOs is vital, as these organizations help ensure compliance with stringent FDA and international standards. The increasing focus on personalized medicine and novel therapies drives demand for small-batch, complex API manufacturing, areas where CDMOs excel due to their flexibility and expertise. Growing collaborations between pharmaceutical firms and CDMOs also foster innovation and accelerate time-to-market, enabling companies to meet better evolving patient better needs.

The market presents significant opportunities, especially in developing biologics, gene therapies, and cell therapies requiring highly specialized API manufacturing. The trend toward continuous manufacturing and flow chemistry offers avenues for CDMOs to improve efficiency and scalability while reducing costs and environmental impact.

U.S. Active Pharmaceutical Ingredients CDMO Market Report Segmentation

This report forecasts revenue growth at country level and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the U.S. active pharmaceutical ingredients CDMO market report based on product, synthesis, drug, workflow, and application.

  • Product Outlook (Revenue, USD Million, 2018 - 2030)
  • Traditional Active Pharmaceutical Ingredient
  • Highly Potent Active Pharmaceutical Ingredient
  • Antibody Drug Conjugate (ADC)
  • Other
  • Synthesis Outlook (Revenue, USD Million, 2018 - 2030)
  • Synthetic
  • Biotech
  • Drug Outlook (Revenue, USD Million, 2018 - 2030)
  • Innovative
  • Generic
  • Workflow Outlook (Revenue, USD Million, 2018 - 2030)
  • Clinical
  • Commercial
  • Application Outlook (Revenue, USD Million, 2018 - 2030)
  • Oncology
  • Hormonal
  • Glaucoma
  • Cardiovascular disease
  • Diabetes
  • Others

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1. Purchased Database
    • 1.3.2. GVR's Internal Database
    • 1.3.3. Secondary Sources and Third-Party Perspectives
    • 1.3.4. Primary Research
  • 1.4. Information Analysis
    • 1.4.1. Data Analysis Models
  • 1.5. Market Formulation and Data Visualization
  • 1.6. Data Validation and Publishing

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. U.S. Active Pharmaceutical Ingredients CDMO Market Variables, Trends and Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
    • 3.2.3. Industry Challenge
  • 3.3. Industry Analysis Tools
    • 3.3.1. PORTER's Analysis
      • 3.3.1.1. Bargaining power of the suppliers
      • 3.3.1.2. Bargaining power of the buyers
      • 3.3.1.3. Threats of substitution
      • 3.3.1.4. Threats from new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Economic and social landscape
      • 3.3.2.3. Technological landscape

Chapter 4. U.S. Active Pharmaceutical Ingredients CDMO Market: Product Estimates and Trend Analysis

  • 4.1. U.S. Active Pharmaceutical Ingredients CDMO Market, By Product: Key Takeaways
  • 4.2. Product Movement Analysis and Market Share, 2024 and 2030
  • 4.3. Market Estimates and Forecasts, By Product, 2018 - 2030 (USD Million)
    • 4.3.1. Traditional Active Pharmaceutical Ingredient
      • 4.3.1.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.2. Highly Potent Active Pharmaceutical Ingredient
      • 4.3.2.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.3. Antibody Drug Conjugate (ADC)
      • 4.3.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.4. Other
      • 4.3.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. U.S. Active Pharmaceutical Ingredients CDMO Market: Synthesis Estimates and Trend Analysis

  • 5.1. U.S. Active Pharmaceutical Ingredients CDMO Market, By Synthesis: Key Takeaways
  • 5.2. Synthesis Movement Analysis and Market Share, 2024 and 2030
  • 5.3. Market Estimates and Forecasts, By Synthesis, 2018 - 2030 (USD Million)
    • 5.3.1. Synthetic
      • 5.3.1.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.3.2. Biotech
      • 5.3.2.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. U.S. Active Pharmaceutical Ingredients CDMO Market: Drug Estimates and Trend Analysis

  • 6.1. U.S. Active Pharmaceutical Ingredients CDMO Market, By Drug: Key Takeaways
  • 6.2. Drug Movement Analysis and Market Share, 2024 and 2030
  • 6.3. Market Estimates and Forecasts, By Drug, 2018 - 2030 (USD Million)
    • 6.3.1. Innovative
      • 6.3.1.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.2. Generic
      • 6.3.2.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. U.S. Active Pharmaceutical Ingredients CDMO Market: Workflow Estimates and Trend Analysis

  • 7.1. U.S. Active Pharmaceutical Ingredients CDMO Market, By Workflow: Key Takeaways
  • 7.2. Workflow Movement Analysis and Market Share, 2024 and 2030
  • 7.3. Market Estimates and Forecasts, By Workflow, 2018 - 2030 (USD Million)
    • 7.3.1. Clinical
      • 7.3.1.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.2. Commercial
      • 7.3.2.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. U.S. Active Pharmaceutical Ingredients CDMO Market: Application Estimates and Trend Analysis

  • 8.1. U.S. Active Pharmaceutical Ingredients CDMO Market, By Application: Key Takeaways
  • 8.2. Application Movement Analysis and Market Share, 2024 and 2030
  • 8.3. Market Estimates and Forecasts, By Application, 2018 - 2030 (USD Million)
    • 8.3.1. Oncology
      • 8.3.1.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.2. Hormonal
      • 8.3.2.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.3. Glaucoma
      • 8.3.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.4. Cardiovascular disease
      • 8.3.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.5. Diabetes
      • 8.3.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.6. Others
      • 8.3.6.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Company Categorization
  • 9.2. Company Market Positioning
  • 9.3. Company Heat Map Analysis
  • 9.4. Company Profiles/Listing
    • 9.4.1. Thermo Fisher Scientific Inc.
      • 9.4.1.1. Company Overview
      • 9.4.1.2. Financial Performance
      • 9.4.1.3. Product Portfolio
      • 9.4.1.4. Recent Developments/ Strategic Initiatives
    • 9.4.2. Novo Group (Catalent, Inc.)
      • 9.4.2.1. Company Overview
      • 9.4.2.2. Financial Performance
      • 9.4.2.3. Product Portfolio
      • 9.4.2.4. Recent Developments/ Strategic Initiatives
    • 9.4.3. Cambrex Corporation
      • 9.4.3.1. Company Overview
      • 9.4.3.2. Financial Performance
      • 9.4.3.3. Product Portfolio
      • 9.4.3.4. Recent Developments/ Strategic Initiatives
    • 9.4.4. Piramal Pharma Limited
      • 9.4.4.1. Company Overview
      • 9.4.4.2. Financial Performance
      • 9.4.4.3. Product Portfolio
      • 9.4.4.4. Recent Developments/ Strategic Initiatives
    • 9.4.5. Corden Pharma
      • 9.4.5.1. Company Overview
      • 9.4.5.2. Financial Performance
      • 9.4.5.3. Product Portfolio
      • 9.4.5.4. Recent Developments/ Strategic Initiatives
    • 9.4.6. Siegfried Holding AG
      • 9.4.6.1. Company Overview
      • 9.4.6.2. Financial Performance
      • 9.4.6.3. Product Portfolio
      • 9.4.6.4. Recent Developments/ Strategic Initiatives
    • 9.4.7. Seqens North America
      • 9.4.7.1. Company Overview
      • 9.4.7.2. Financial Performance
      • 9.4.7.3. Product Portfolio
      • 9.4.7.4. Recent Developments/ Strategic Initiatives
    • 9.4.8. SK pharmteco Inc.
      • 9.4.8.1. Company Overview
      • 9.4.8.2. Financial Performance
      • 9.4.8.3. Product Portfolio
      • 9.4.8.4. Recent Developments/ Strategic Initiatives
    • 9.4.9. Noramco.
      • 9.4.9.1. Company Overview
      • 9.4.9.2. Financial Performance
      • 9.4.9.3. Product Portfolio
      • 9.4.9.4. Recent Developments/ Strategic Initiatives
    • 9.4.10. BSP Pharmaceuticals
      • 9.4.10.1. Company Overview
      • 9.4.10.2. Financial Performance
      • 9.4.10.3. Product Portfolio
      • 9.4.10.4. Recent Developments/ Strategic Initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 U.S active pharmaceutical ingredients CDMO market: key market driver analysis
  • Table 3 U.S active pharmaceutical ingredients CDMO market: Key market restraint analysis
  • Table 4 U.S active pharmaceutical ingredients CDMO market estimates and forecast, by product (USD Million)
  • Table 5 U.S active pharmaceutical ingredients CDMO market estimates and forecast, by synthesis (USD Million)
  • Table 6 U.S active pharmaceutical ingredients CDMO market estimates and forecast, by drug (USD Million)
  • Table 7 U.S active pharmaceutical ingredients CDMO market estimates and forecast, by workflow (USD Million)
  • Table 8 U.S active pharmaceutical ingredients CDMO market estimates and forecast, by application (USD Million)
  • Table 9 Recent developments and impact analysis by key market participants
  • Table 10 Company heat map analysis, 2024
  • Table 11 Companies implementing key strategies

List of Figures

  • Fig. 1 U.S active pharmaceutical ingredients CDMO market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value chain-based sizing and forecasting
  • Fig. 7 Parent market analysis
  • Fig. 8 Market formulation and validation
  • Fig. 9 U.S active pharmaceutical ingredients CDMO market snapshot
  • Fig. 10 U.S active pharmaceutical ingredients CDMO market segment snapshot
  • Fig. 11 U.S active pharmaceutical ingredients CDMO market competitive landscape snapshot
  • Fig. 12 Market research process
  • Fig. 13 Market driver relevance analysis (Current and future impact)
  • Fig. 14 Market restraint relevance analysis (Current and future impact)
  • Fig. 15 U.S active pharmaceutical ingredients CDMO market: Product outlook key takeaways (USD Million)
  • Fig. 16 U.S active pharmaceutical ingredients CDMO market: Product movement analysis 2024 & 2030 (USD Million)
  • Fig. 17 Traditional Active Pharmaceutical Ingredient market estimates & forecasts, 2018 - 2030 (USD Million)
  • Fig. 18 Highly Potent Active Pharmaceutical Ingredient market estimates & forecasts, 2018 - 2030 (USD Million)
  • Fig. 19 Antibody Drug Conjugate (ADC)s market estimates & forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Others market estimates & forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 U.S active pharmaceutical ingredients CDMO market: Synthesis outlook key takeaways (USD Million)
  • Fig. 22 U.S active pharmaceutical ingredients CDMO market: Synthesis movement analysis 2024 & 2030 (USD Million)
  • Fig. 23 Synthetic market estimates & forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 Biotech market estimates & forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 U.S active pharmaceutical ingredients CDMO market: Drug outlook key takeaways (USD Million)
  • Fig. 26 U.S active pharmaceutical ingredients CDMO market: Drug movement analysis 2024 & 2030 (USD Million)
  • Fig. 27 Innovative market estimates & forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 Generics market estimates & forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 Distributed recipient drugs market estimates & forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 U.S active pharmaceutical ingredients CDMO market: Workflow outlook key takeaways (USD Million)
  • Fig. 31 U.S active pharmaceutical ingredients CDMO market: Workflow movement analysis 2024 & 2030 (USD Million)
  • Fig. 32 Clinical market estimates & forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 Commercial market estimates & forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 U.S active pharmaceutical ingredients CDMO market: Application outlook key takeaways (USD Million)
  • Fig. 35 U.S active pharmaceutical ingredients CDMO market: Application movement analysis 2024 & 2030 (USD Million)
  • Fig. 36 Oncology market estimates & forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Hormonal market estimates & forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Glaucoma market estimates & forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Cardiovascular disease market estimates & forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Diabetes market estimates & forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Others market estimates & forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Strategy framework
  • Fig. 43 Company categorization